SCHEMBL1744910

SCHEMBL1744910

CC(C)(C)OC(=O)CCCCCCCCCCCCCCC(=O)Nc1ccc(C(=O)ON2C(=O)CCC2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 3/20 0.51
HTR1A P08908 2/20 0.47
HTR7 P34969 2/20 0.47
ALDH1A1 P00352 3/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.41
HDAC3 O15379 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
HTT P42858 1/20 0.40
CASP1 P29466 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GLA P06280 1/20 0.39
ATM Q13315 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11914021 0.88 HTR1A (0.49) HDAC8HTR1AHTR7ALDH1A1HPGD
SCHEMBL557453 0.88 HDAC8 (0.45) HDAC8HTR1AHTR7ALDH1A1HPGD
SCHEMBL1897841 0.86 HDAC8 (0.43) HDAC8HTR1AHTR7ALDH1A1HPGD
SCHEMBL2927183 0.84 HSD17B10 (0.42) HDAC8HTR1AHTR7ALDH1A1HPGD
SCHEMBL557953 0.84 HSD17B10 (0.42) HDAC8HTR1AHTR7ALDH1A1HPGD
SCHEMBL15061945 0.83 HDAC8 (0.41) HDAC8HTR1AHTR7ALDH1A1HPGD
SCHEMBL557990 0.83 HDAC8 (0.60) HDAC8HTR1AHTR7MEN1KMT2A
SCHEMBL13498680 0.81 ALDH1A1 (0.46) ALDH1A1HPGDMEN1KMT2A
SCHEMBL558129 0.81 HDAC8 (0.40) HDAC8HTR1AHTR7ALDH1A1HPGD
SCHEMBL1744913 0.79 HDAC8 (0.61) HDAC8HTR1AHTR7ALDH1A1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2386572-B1 Insulin derivative NOVO NORDISK AS (DK) 2015-07-08 EP disclosed
US-8933021-B2 Insulin derivative NOVO NORDISK A/S (DK) 2015-01-13 US disclosed
EP-2015770-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2012-09-26 EP disclosed
EP-2386572-A1 Insulin derivative Novo Nordisk A/S (DK) 2011-11-16 EP disclosed
US-8039101-B2 Radio-opaque dental prosthetic member Societe de Recherches Techniques Dentaires-R.T.D. (FR) 2011-10-18 US disclosed
US-20090239785-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-09-24 US disclosed
EP-2015770-A2 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2009-01-21 EP disclosed
WO-2007128817-A2 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239785-A1 Insulin Derivative IAPP, INSR, GPR119 HDAC8 3012/4885HTR1A 3936/4885HTR7 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.